Log in or register to see all Alerts
New HTA Decisions in Germany
June 2020
Drug name
SKYRIZI™ (risankizumab)
Company
AbbVie Deutschland
Decision date
22/11/2019
Therapeutic area
Skin conditions
Therapeutic sub area
Psoriasis
G-BA decision date
22/11/2019
Orphan Drug?
No
Decision
No change from previous decision
Indication
Adult patients with moderate to severe plaque psoriasis that are not eligible for conventional treatment as part of a first-line systemic therapy Main comparator: - Adalimumab - Guselkumab - Ixekizumab - Secukinumab
Decision
No change from previous decision
Indication
Adult patients with moderate to severe plaque psoriasis for whom conventional therapy is not tolerated or not successful at alleviating symptoms Main comparator: - Adalimumab - Guselkumab - Infliximab - Ixekizumab - Secukinumab - Ustekinumab
Decision Detail
This addendum to commission provided additional data on HRQoL, as well as additional sensitivity analyses, and a recalculated target population. Nevertheless, the additional data was not sufficient to change the original benefit assessment.
Summary
In this addendum to commission, there was no change in benefit from the original assessment.